MedTech Dive June 10, 2024
Elise Reuter

Abbott will launch two over-the-counter glucose monitors in the U.S., competing directly with Dexcom’s Stelo.

Dive Brief:

  • Abbott said Monday it will launch two over-the-counter continuous glucose monitors after receiving clearance from the Food and Drug Administration.
  • One product is the company’s Lingo device, sold as a wellness product for people who do not have diabetes. The other is Abbott’s new Libre Rio device, which is intended for adults with Type 2 diabetes who do not use insulin, posing a direct challenge to Dexcom’s Stelo device.
  • After Lingo was cleared last week, RBC Capital Markets analyst Shagun Singh wrote the over-the-counter nod could offer a more than $1 billion sales opportunity for Abbott.

Dive Insight:

Abbott had...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
Danaher setting up labs to support companion diagnostic development
Q Bio Secures $27M to Expand Full-Body MRI with Mark I Scanner
Advanced diagnostics: Patient-centered innovation
GE HealthCare to acquire clinical AI company in $51M deal
Abbott previews PFA, over-the-counter CGM markets

Share This Article